Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

pectively. The weighted average shares used in computing loss per share attributable to common stockholders exclude anti-dilutive securities such as stock options and warrants.

Cash, cash equivalents and short-term investments were approximately $30.8 million as of September 30, 2008, compared to $38.0 million at June 30, 2008.

Stephen Ghiglieri, CFO, commented, "In this difficult financial market, we are dedicating our financial resources primarily to obtain marketing approvals for NGX-4010. By pursuing this focused strategy, we believe our existing cash resources are sufficient to move us through expected regulatory decisions in both the U.S. and Europe, and potentially into early 2010. Our objective is to ensure an effective launch of NGX-4010, if approved, in both Europe and the United States. We intend to achieve this through effective cost management, including a near-term focus on activities for NGX-4010 that support the ongoing regulatory review processes and our reimbursement strategies and through commercial partnerships and other non-equity sources of funding. In addition, we anticipate that these other sources of funding could create opportunities to more rapidly advance our development initiatives in addition to effectively launching NGX-4010 in the United States. Given the current state of the equity markets, we have no current intention to raise equity capital in the public markets."

Clinical Development Update

NeurogesX' near-term clinical focus is to secure regulatory approvals of the NDA and MAA for NGX-4010. Regarding the potential for additional clinical studies in HIV-DSP and/or PDN, NeurogesX continues to evaluate the appropriate scope and nature of future studies, if any, in these indications. The timing for initiating such studies will be based in part on availability of financial resources.

NGX-1998, the Company's second-generation, liquid formulation of high-concentration capsaicin (10% trans-capsaicin) is
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... May 11 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming Bank ... Mr. Patterson,s presentation is scheduled to begin on Wednesday, ... live webcast of the presentation by logging on to the ...
... NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... to,improving health through the development, manufacture and commercialization of,a ... products in China,today announced financial results for the first ... Financial Results , Revenue ...
... May 9 Oxford Biomedica,s,second attempt to dismiss Bavarian ... Instead of denying infringement, Oxford Biomedica,made yet another attempt ... TroVax(R) was still evaluated in clinical trials. The court ... based on the,substance of the patents. , ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2009 Financial Results 2American Oriental Bioengineering Reports First Quarter 2009 Financial Results 3American Oriental Bioengineering Reports First Quarter 2009 Financial Results 4American Oriental Bioengineering Reports First Quarter 2009 Financial Results 5American Oriental Bioengineering Reports First Quarter 2009 Financial Results 6American Oriental Bioengineering Reports First Quarter 2009 Financial Results 7The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Just as scientists finished sequencing the human genome, they ... DNA produces proteins to sustain life, they found microRNA. ... channel in biology, allowing scientists to more closely examine ... tick. "This is a pivotal mechanism for solving ...
... Ore Oregon Health & Science University researchers, along ... uncovering new information about the mind by studying the ... this research will one day provide new tools for ... treatments. The researchers, latest findings are published in the ...
... Universit de Montreal (UdeM) and the Montreal Neurological Institute ... support nerve cell (neuron) survival also play an active ... the eye. The findings, published this week in The ... streamlined therapies for a variety of acute and chronic ...
Cached Biology News:Meet DNA's personal assistants 2OHSU researchers study the idling brain 2Cell's split personality is a major discovery into neurological diseases 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: